Cardioplegic strategies for calcium control: low Ca(2+), high Mg(2+), citrate, or Na(+)/H(+) exchange inhibitor

Y Fukuhiro1, M Wowk, R Ou

  • 1Cardiac Surgical Research Unit, Alfred Hospital and Baker Medical Research Institute, St Kilda Central, Melbourne, Victoria, Australia.

Circulation
|November 18, 2000
PubMed

Insights

Reducing calcium (Ca2+) in cardioplegic solutions (CP) benefits heart function after ischemia. The Na+/H+ exchange inhibitor HOE-642 also preserves myocardial function, offering an alternative to Ca2+ reduction.

Area of Science:

  • Cardiovascular Physiology
  • Cardiac Surgery
  • Ischemia-Reperfusion Injury

Background:

  • Calcium (Ca2+) overload is a key factor in cardioplegic ischemia-reperfusion injury.
  • Conventional methods to control Ca2+ overload involve reducing Ca2+ in cardioplegic solutions (CP).
  • Emerging research suggests Na+/H+ exchange inhibitors may also prevent Ca2+ overload.

Purpose of the Study:

  • To compare the efficacy of four crystalloid cardioplegic solutions (CPs) in minimizing Ca2+ overload against standard Mg2+-containing CP.
  • To evaluate low Ca2+ CP (0.25 mmol/L), citrate CP with normal (1 mmol/L) or high (9 mmol/L) Mg2+, and CP with the Na+/H+ exchange inhibitor HOE-642.
  • To assess the in vitro effect of citrate titration on free Ca2+ and Mg2+ levels in CPs.

Main Methods:

  • Isolated working rat heart preparations were used.
  • Hearts were subjected to 60 minutes of 37°C arrest and reperfusion with various CPs.
  • Cardiac performance (aortic flow) and myocardial high-energy phosphates were measured post-reperfusion.

Main Results:

  • Citrate addition to CP reduced both Mg2+ and Ca2+; however, it significantly impaired postischemic function, especially with high Mg2+.
  • Low Ca2+ CP (0.25 mmol/L) significantly improved postischemic cardiac function recovery compared to standard CP (1.0 mmol/L Ca2+).
  • The addition of HOE-642 (1 µmol/L) to CP significantly enhanced postischemic function, demonstrating efficacy comparable to direct Ca2+ reduction.

Conclusions:

  • Lowering Ca2+ concentration in Mg2+-containing cardioplegia is beneficial for myocardial preservation.
  • Citrate chelation of Ca2+ is detrimental to crystalloid-perfused rat hearts, particularly when combined with high Mg2+ concentrations.
  • HOE-642 in CP is as effective as direct Ca2+ reduction in preserving ischemic myocardium.
Abstract

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
2.4K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.8K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.9K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
444
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.6K